This article was originally published in abbreviated form at an Spanish on-line journal [http://www.siicsalud.com/dato/dat048/06406023a.htm]. The attached pdf link is the full version, not published previously. The article summarizes the issues related to phosphate retention, excess calcium absorption due to the use of calcium-containing phosphate binders and some of the data related to adverse cardiovascular consequences related to the exclusive use of such binders. This is followed by a discussion of calcium-free phosphate binders such as sevelamer and lanthanum carbonate. For more up-to-date information, the reader is encouraged to read some of the excellent recent reviews such as the one by Malindretos, published this month in Expert Opinion in Pharmacotherapy.
- Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- U.S. FDA APPROVES AURYXIA® (FERRIC CITRATE) TABLETS AS A TREATMENT FOR PEOPLE WITH IRON DEFICIENCY ANEMIA AND CHRONIC KIDNEY DISEASE, NOT ON DIALYSIS
- Pharmalink AB announces the publication in Lancet of Phase 2b trial of Nefecon in primary IgA nephropathy. The data were also presented at the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) conference (Madrid, Spain)
- Amgen and AbbVie reach a settlement on Humira biosimilar patent litigation
- Merck Provides Update on REVEAL Outcomes Study of Anacetrapib